A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01)

Louise Skau Rasmussen, Stine B. Winther, Inna M. Chen, Britta Weber, Lise Ventzel, Gabor Liposits, Julia Sidenius Johansen, Sönke Detlefsen, Ida Egendal, Susy Shim, Signe Christensen, Per Pfeiffer, Morten Ladekarl*

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

1 Citation (Scopus)
29 Downloads (Pure)

Fingerprint

Dive into the research topics of 'A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01)'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology